In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria

Clinical Infectious Diseases

Volumn 23, Issue SUPPL. 1, 1996, Pages

  Nord, Carl Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOXITIN; CIPROFLOXACIN; CLINDAMYCIN; IMIPENEM; LOMEFLOXACIN; METRONIDAZOLE; OFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN; SPARFLOXACIN;

ANAEROBIC BACTERIUM; ANAEROBIC INFECTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; FUSOBACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOSTREPTOCOCCUS; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL;

EID: 0029806592     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.supplement_1.s15     Document Type: Article

References (15)

1. Goldstein EJ. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States. Clin Infect Dis 1993; 16(suppl 4):S377-81.
2. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Manual of clinical microbiology. 6th ed. Washington, DC: American Society for Microbiology, 1995.
3. National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard M11-A3. 3rd ed. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1993.
4. Finegold SM. Anaerobic infections in humans: an overview. Anaerobe 1995; 1:3-9.
5. Carbon C, Rubinstein E, Adam D, Moellering R, Waldvogel F. Proceedings of the 5th International Symposium on New Quinolones. Drugs 1995; 49(suppl 2): 1-505.
6. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994;38:2471-6.
7. Wexler HM, Molitoris E, Finegold SM. In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria. Diagn Microbiol Infect Dis 1994; 19:129-33.
8. Gootz TD, Brighty KE, Anderson MR, et al. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagn Microbiol Infect Dis 1994; 19:235-43.
9. Neu HC, Chin NX. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother 1994;38:2615-22.
10. Goldstein EJ, Citron DM. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother 1992;36: 1158-62.
11. Wexler HM, Molitoris E, Reeves D, Finegold SM. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria. J Antimicrob Chemother 1994;34:579-84.
12. Sato K, Hoshino K, Tanaka M, Hayakawa I, Osada Y. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother 1992;36:1491-8.
13. Marshall SA, Jones RN. In vitro activity of DU-6859a, a new fluoro-cyclopropyl quinolone. Antimicrob Agents Chemother 1993;37: 2747-53.
14. Wexler HM, Molitoris E, Reeves D, Finegold SM. In vitro activity of DU-6859a against anaerobic bacteria. Antimicrob Agents Chemother 1994; 38:2504-9.
15. Nakane T, Iyobe S, Sato K, Mitsuhashi S. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Antimicrob Agents Chemother 1995;39:2822-6.